Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Brain cancer

Solute carrier family 2 member 3 (SLC2A3; GLUT3)

Studies in patient samples, mice and cell culture suggest targeting GLUT3 could help treat brain cancer. In cultured brain tumor-initiating cells (BTICs), GLUT3 mRNA and protein expression were greater than that in non-BTICs. In BTICs, small hairpin RNA knockdown of GLUT3 decreased cell growth and BTIC-mediated tumor propagation in mice compared with no knockdown. In patient brain tumor samples, high GLUT3 expression correlated with poor survival. Next steps could include design and synthesis of GLUT3 inhibitors for testing in preclinical models of brain cancer.

SciBX 6(39); doi:10.1038/scibx.2013.1087
Published online Oct. 10, 2013

Patent and licensing status unavailable

Flavahan, W.A. et al. Nat. Neurosci.; published online Sept. 1, 2013;
doi:10.1038/nn.3510
Contact: Jeremy N. Rich, Cleveland Clinic, Cleveland, Ohio
e-mail:

richj@ccf.org